25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

BIOMARIN PHARM (BM8.SG)
Buy, Hold or Sell?

Let's analyze BIOMARIN PHARM (BM8.SG) together

I guess you are interested in BIOMARIN PHARM (BM8.SG). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BIOMARIN PHARM (BM8.SG). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about BIOMARIN PHARM (BM8.SG)

I send you an email if I find something interesting about BIOMARIN PHARM (BM8.SG).

1. Quick Overview

1.1. Quick analysis of BIOMARIN PHARM (BM8.SG) (30 sec.)










1.2. What can you expect buying and holding a share of BIOMARIN PHARM (BM8.SG)? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€27.32
Expected worth in 1 year
€30.46
How sure are you?
90.5%

+ What do you gain per year?

Total Gains per Share
€3.14
Return On Investment
4.8%

For what price can you sell your share?

Current Price per Share
€65.32
Expected price per share
€57.46 - €68.22
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of BIOMARIN PHARM (BM8.SG) (5 min.)




Live pricePrice per Share (EOD)
€65.32
Intrinsic Value Per Share
€51.86 - €62.08
Total Value Per Share
€79.19 - €89.41

2.2. Growth of BIOMARIN PHARM (BM8.SG) (5 min.)




Is BIOMARIN PHARM (BM8.SG) growing?

Current yearPrevious yearGrowGrow %
How rich?$5.6b$4.8b$535.2m10.0%

How much money is BIOMARIN PHARM (BM8.SG) making?

Current yearPrevious yearGrowGrow %
Making money$106.7m$41.9m$64.8m60.7%
Net Profit Margin14.9%7.0%--

How much money comes from the company's main activities?

2.3. Financial Health of BIOMARIN PHARM (BM8.SG) (5 min.)




2.4. Comparing to competitors in the Other industry (5 min.)




  Industry Rankings (Other)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of BIOMARIN PHARM (BM8.SG)?

Welcome investor! BIOMARIN PHARM (BM8.SG)'s management wants to use your money to grow the business. In return you get a share of BIOMARIN PHARM (BM8.SG).

First you should know what it really means to hold a share of BIOMARIN PHARM (BM8.SG). And how you can make/lose money.

Speculation

The Price per Share of BIOMARIN PHARM (BM8.SG) is €65.32. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of BIOMARIN PHARM (BM8.SG).
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in BIOMARIN PHARM (BM8.SG), you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €27.32. Based on the TTM, the Book Value Change Per Share is €0.78 per quarter. Based on the YOY, the Book Value Change Per Share is €0.35 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of BIOMARIN PHARM (BM8.SG).

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.651.0%0.560.9%0.220.3%0.410.6%0.350.5%
Usd Book Value Change Per Share1.251.9%0.851.3%0.380.6%0.610.9%1.412.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.251.9%0.851.3%0.380.6%0.610.9%1.412.2%
Usd Price Per Share69.32-77.61-93.50-84.79-74.09-
Price to Earnings Ratio26.46-35.48-123.01--939.82--772.92-
Price-to-Total Gains Ratio55.40-106.93-373.52--79.91--75.88-
Price to Book Ratio2.34-2.77-3.65-3.57-3.17-
Price-to-Total Gains Ratio55.40-106.93-373.52--79.91--75.88-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share70.90486
Number of shares14
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.850.61
Usd Total Gains Per Share0.850.61
Gains per Quarter (14 shares)11.928.61
Gains per Year (14 shares)47.6834.43
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10483803424
20958606958
30143134010392
401911820138126
502382300172160
602862780207194
703343260241228
803813740275262
904294220310296
1004774700344330

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%10.02.00.083.3%15.05.00.075.0%16.05.00.076.2%16.05.00.076.2%
Book Value Change Per Share4.00.00.0100.0%12.00.00.0100.0%18.02.00.090.0%19.02.00.090.5%19.02.00.090.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%18.02.00.090.0%19.02.00.090.5%19.02.00.090.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of BIOMARIN PHARM (BM8.SG) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.1530.784+47%0.355+225%0.566+103%1.301-11%
Book Value Per Share--27.32325.926+5%23.608+16%22.363+22%19.303+42%
Current Ratio--5.3253.849+38%3.686+44%4.170+28%4.049+32%
Debt To Asset Ratio--0.1900.229-17%0.275-31%0.279-32%0.288-34%
Debt To Equity Ratio--0.2350.298-21%0.379-38%0.392-40%0.409-42%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--10955948607.14012146187250.300-10%14524771724.580-25%12917797711.125-15%12883369058.983-15%
Eps--0.6030.516+17%0.205+194%0.382+58%0.321+88%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--3.9794.662-15%6.525-39%6.519-39%6.555-39%
Free Cash Flow Per Share--0.7980.575+39%0.063+1172%0.172+365%0.163+391%
Free Cash Flow To Equity Per Share--0.812-0.062+108%0.040+1948%0.081+897%0.078+945%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--62.085--------
Intrinsic Value_10Y_min--51.863--------
Intrinsic Value_1Y_max--1.692--------
Intrinsic Value_1Y_min--1.659--------
Intrinsic Value_3Y_max--8.536--------
Intrinsic Value_3Y_min--8.079--------
Intrinsic Value_5Y_max--19.541--------
Intrinsic Value_5Y_min--17.840--------
Market Cap--12182019747.14013608230218.700-10%16207416529.680-25%14510230966.265-16%12660147578.794-4%
Net Profit Margin--0.1670.149+12%0.070+139%0.139+20%0.112+49%
Operating Margin----0%-0%0.009-100%0.010-100%
Operating Ratio--0.9661.038-7%1.128-14%1.203-20%1.217-21%
Pb Ratio2.391+2%2.3372.772-16%3.651-36%3.569-35%3.172-26%
Pe Ratio27.065+2%26.46035.483-25%123.006-78%-939.818+3652%-772.916+3021%
Price Per Share65.320+2%63.86071.500-11%86.133-26%78.114-18%68.255-6%
Price To Free Cash Flow Ratio20.454+2%19.997100.922-80%-101.015+605%-50.753+354%-86.371+532%
Price To Total Gains Ratio56.667+2%55.400106.927-48%373.517-85%-79.906+244%-75.875+237%
Quick Ratio--1.4091.149+23%1.342+5%1.466-4%1.465-4%
Return On Assets--0.0180.015+16%0.006+182%0.012+47%0.010+81%
Return On Equity--0.0220.020+11%0.009+152%0.017+27%0.014+57%
Total Gains Per Share--1.1530.784+47%0.355+225%0.566+103%1.301-11%
Usd Book Value--5657778391.1745357674865.466+6%4822398635.545+17%4518161764.430+25%4269047914.970+33%
Usd Book Value Change Per Share--1.2510.851+47%0.385+225%0.615+103%1.412-11%
Usd Book Value Per Share--29.65928.143+5%25.626+16%24.276+22%20.953+42%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--11892682213.05113184686260.201-10%15766639707.032-25%14022269415.426-15%13984897113.526-15%
Usd Eps--0.6550.560+17%0.223+194%0.414+58%0.349+88%
Usd Free Cash Flow--165321816.733118851304.795+39%12911517.091+1180%35228182.417+369%24559331.447+573%
Usd Free Cash Flow Per Share--0.8670.624+39%0.068+1172%0.186+365%0.177+391%
Usd Free Cash Flow To Equity Per Share--0.882-0.067+108%0.043+1948%0.088+897%0.084+945%
Usd Market Cap--13223582435.52114771733902.399-10%17593150642.968-25%15750855713.880-16%13742590196.781-4%
Usd Price Per Share70.905+2%69.32077.613-11%93.497-26%84.793-18%74.091-6%
Usd Profit--124938327.132106710758.868+17%41909682.519+198%76551386.871+63%62799192.889+99%
Usd Revenue--747285050.494713452065.895+5%604783880.237+24%553777037.964+35%532480209.495+40%
Usd Total Gains Per Share--1.2510.851+47%0.385+225%0.615+103%1.412-11%
 EOD+2 -4MRQTTM+28 -7YOY+27 -85Y+26 -1010Y+22 -14

3.3 Fundamental Score

Let's check the fundamental score of BIOMARIN PHARM (BM8.SG) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1527.065
Price to Book Ratio (EOD)Between0-12.391
Net Profit Margin (MRQ)Greater than00.167
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.409
Current Ratio (MRQ)Greater than15.325
Debt to Asset Ratio (MRQ)Less than10.190
Debt to Equity Ratio (MRQ)Less than10.235
Return on Equity (MRQ)Greater than0.150.022
Return on Assets (MRQ)Greater than0.050.018
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of BIOMARIN PHARM (BM8.SG) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.878
Ma 20Greater thanMa 5065.222
Ma 50Greater thanMa 10063.096
Ma 100Greater thanMa 20062.761
OpenGreater thanClose64.300
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About BIOMARIN PHARM (BM8.SG)

  • Other
  • 0

There is no Profile data available for BM8.SG.

Fundamental data was last updated by Penke on 2025-03-11 19:31:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit BIOMARIN PHARM (BM8.SG) earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare BIOMARIN PHARM (BM8.SG) to the Other industry mean.
  • A Net Profit Margin of 16.7% means that €0.17 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BIOMARIN PHARM (BM8.SG):

  • The MRQ is 16.7%. The company is making a huge profit. +2
  • The TTM is 14.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ16.7%TTM14.9%+1.8%
TTM14.9%YOY7.0%+7.9%
TTM14.9%5Y13.9%+1.0%
5Y13.9%10Y11.2%+2.7%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ16.7%5.6%+11.1%
TTM14.9%5.9%+9.0%
YOY7.0%6.1%+0.9%
5Y13.9%6.2%+7.7%
10Y11.2%6.1%+5.1%
4.3.1.2. Return on Assets

Shows how efficient BIOMARIN PHARM (BM8.SG) is using its assets to generate profit.

  • Above 5% is considered healthy but always compare BIOMARIN PHARM (BM8.SG) to the Other industry mean.
  • 1.8% Return on Assets means that BIOMARIN PHARM (BM8.SG) generated €0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BIOMARIN PHARM (BM8.SG):

  • The MRQ is 1.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM1.5%+0.3%
TTM1.5%YOY0.6%+0.9%
TTM1.5%5Y1.2%+0.3%
5Y1.2%10Y1.0%+0.2%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8%1.3%+0.5%
TTM1.5%1.1%+0.4%
YOY0.6%1.3%-0.7%
5Y1.2%1.3%-0.1%
10Y1.0%1.3%-0.3%
4.3.1.3. Return on Equity

Shows how efficient BIOMARIN PHARM (BM8.SG) is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare BIOMARIN PHARM (BM8.SG) to the Other industry mean.
  • 2.2% Return on Equity means BIOMARIN PHARM (BM8.SG) generated €0.02 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BIOMARIN PHARM (BM8.SG):

  • The MRQ is 2.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.2%TTM2.0%+0.2%
TTM2.0%YOY0.9%+1.1%
TTM2.0%5Y1.7%+0.3%
5Y1.7%10Y1.4%+0.3%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2%3.7%-1.5%
TTM2.0%3.4%-1.4%
YOY0.9%3.9%-3.0%
5Y1.7%3.9%-2.2%
10Y1.4%3.8%-2.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of BIOMARIN PHARM (BM8.SG).

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient BIOMARIN PHARM (BM8.SG) is operating .

  • Measures how much profit BIOMARIN PHARM (BM8.SG) makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare BIOMARIN PHARM (BM8.SG) to the Other industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BIOMARIN PHARM (BM8.SG):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y0.9%-0.9%
5Y0.9%10Y1.0%-0.1%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.7%-12.7%
TTM-8.2%-8.2%
YOY-7.8%-7.8%
5Y0.9%4.4%-3.5%
10Y1.0%6.8%-5.8%
4.3.2.2. Operating Ratio

Measures how efficient BIOMARIN PHARM (BM8.SG) is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Other industry mean).
  • An Operation Ratio of 0.97 means that the operating costs are €0.97 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of BIOMARIN PHARM (BM8.SG):

  • The MRQ is 0.966. The company is less efficient in keeping operating costs low.
  • The TTM is 1.038. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.966TTM1.038-0.072
TTM1.038YOY1.128-0.090
TTM1.0385Y1.203-0.165
5Y1.20310Y1.217-0.014
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9661.313-0.347
TTM1.0381.355-0.317
YOY1.1281.375-0.247
5Y1.2031.324-0.121
10Y1.2171.381-0.164
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of BIOMARIN PHARM (BM8.SG).

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if BIOMARIN PHARM (BM8.SG) is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Other industry mean).
  • A Current Ratio of 5.33 means the company has €5.33 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of BIOMARIN PHARM (BM8.SG):

  • The MRQ is 5.325. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.849. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.325TTM3.849+1.477
TTM3.849YOY3.686+0.163
TTM3.8495Y4.170-0.321
5Y4.17010Y4.049+0.121
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3251.426+3.899
TTM3.8491.416+2.433
YOY3.6861.538+2.148
5Y4.1701.562+2.608
10Y4.0491.496+2.553
4.4.3.2. Quick Ratio

Measures if BIOMARIN PHARM (BM8.SG) is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare BIOMARIN PHARM (BM8.SG) to the Other industry mean.
  • A Quick Ratio of 1.41 means the company can pay off €1.41 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BIOMARIN PHARM (BM8.SG):

  • The MRQ is 1.409. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.149. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.409TTM1.149+0.260
TTM1.149YOY1.342-0.193
TTM1.1495Y1.466-0.317
5Y1.46610Y1.465+0.001
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4090.531+0.878
TTM1.1490.553+0.596
YOY1.3420.603+0.739
5Y1.4660.606+0.860
10Y1.4650.609+0.856
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of BIOMARIN PHARM (BM8.SG).

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of BIOMARIN PHARM (BM8.SG) assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare BIOMARIN PHARM (BM8.SG) to Other industry mean.
  • A Debt to Asset Ratio of 0.19 means that BIOMARIN PHARM (BM8.SG) assets are financed with 19.0% credit (debt) and the remaining percentage (100% - 19.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BIOMARIN PHARM (BM8.SG):

  • The MRQ is 0.190. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.229. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.190TTM0.229-0.038
TTM0.229YOY0.275-0.046
TTM0.2295Y0.279-0.051
5Y0.27910Y0.288-0.009
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1900.520-0.330
TTM0.2290.529-0.300
YOY0.2750.523-0.248
5Y0.2790.555-0.276
10Y0.2880.564-0.276
4.5.4.2. Debt to Equity Ratio

Measures if BIOMARIN PHARM (BM8.SG) is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare BIOMARIN PHARM (BM8.SG) to the Other industry mean.
  • A Debt to Equity ratio of 23.5% means that company has €0.24 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BIOMARIN PHARM (BM8.SG):

  • The MRQ is 0.235. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.298. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.235TTM0.298-0.063
TTM0.298YOY0.379-0.081
TTM0.2985Y0.392-0.094
5Y0.39210Y0.409-0.017
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2351.095-0.860
TTM0.2981.128-0.830
YOY0.3791.155-0.776
5Y0.3921.338-0.946
10Y0.4091.429-1.020
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings BIOMARIN PHARM (BM8.SG) generates.

  • Above 15 is considered overpriced but always compare BIOMARIN PHARM (BM8.SG) to the Other industry mean.
  • A PE ratio of 26.46 means the investor is paying €26.46 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BIOMARIN PHARM (BM8.SG):

  • The EOD is 27.065. Based on the earnings, the company is overpriced. -1
  • The MRQ is 26.460. Based on the earnings, the company is overpriced. -1
  • The TTM is 35.483. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD27.065MRQ26.460+0.605
MRQ26.460TTM35.483-9.023
TTM35.483YOY123.006-87.523
TTM35.4835Y-939.818+975.301
5Y-939.81810Y-772.916-166.902
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD27.06514.089+12.976
MRQ26.46013.537+12.923
TTM35.48312.493+22.990
YOY123.00611.191+111.815
5Y-939.81812.976-952.794
10Y-772.91613.175-786.091
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BIOMARIN PHARM (BM8.SG):

  • The EOD is 20.454. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 19.997. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 100.922. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD20.454MRQ19.997+0.457
MRQ19.997TTM100.922-80.925
TTM100.922YOY-101.015+201.937
TTM100.9225Y-50.753+151.675
5Y-50.75310Y-86.371+35.618
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD20.4548.643+11.811
MRQ19.9978.169+11.828
TTM100.9227.139+93.783
YOY-101.0155.896-106.911
5Y-50.7533.220-53.973
10Y-86.3713.714-90.085
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of BIOMARIN PHARM (BM8.SG) is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Other industry mean).
  • A PB ratio of 2.34 means the investor is paying €2.34 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of BIOMARIN PHARM (BM8.SG):

  • The EOD is 2.391. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.337. Based on the equity, the company is underpriced. +1
  • The TTM is 2.772. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.391MRQ2.337+0.053
MRQ2.337TTM2.772-0.435
TTM2.772YOY3.651-0.879
TTM2.7725Y3.569-0.797
5Y3.56910Y3.172+0.397
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD2.3911.532+0.859
MRQ2.3371.404+0.933
TTM2.7721.428+1.344
YOY3.6511.405+2.246
5Y3.5691.718+1.851
10Y3.1721.715+1.457
4.6.2. Total Gains per Share

2.4. Latest News of BIOMARIN PHARM (BM8.SG)

Does BIOMARIN PHARM (BM8.SG) still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from BIOMARIN PHARM (BM8.SG) to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-03-08
09:37
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?Read
2025-03-05
15:40
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-TermRead
2025-02-28
17:40
BMRN or CSLLY: Which Is the Better Value Stock Right Now?Read
2025-02-28
15:45
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-TermRead
2025-02-24
22:05
BioMarin Announces Appointment of Timothy P. Walbert to Board of DirectorsRead
2025-02-24
18:45
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons WhyRead
2025-02-21
12:25
BioMarin Pharmaceutical Full Year 2024 Earnings: Beats ExpectationsRead
2025-02-19
23:30
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key MetricsRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets6,988,940
Total Liabilities1,330,950
Total Stockholder Equity5,657,990
 As reported
Total Liabilities 1,330,950
Total Stockholder Equity+ 5,657,990
Total Assets = 6,988,940

Assets

Total Assets6,988,940
Total Current Assets3,232,427
Long-term Assets3,756,513
Total Current Assets
Cash And Cash Equivalents 942,842
Short-term Investments 194,864
Net Receivables 660,535
Inventory 1,232,653
Other Current Assets 201,533
Total Current Assets  (as reported)3,232,427
Total Current Assets  (calculated)3,232,427
+/-0
Long-term Assets
Property Plant Equipment 1,043,041
Goodwill 196,199
Long Term Investments 521,238
Intangible Assets 255,278
Long-term Assets Other 251,391
Long-term Assets  (as reported)3,756,513
Long-term Assets  (calculated)2,267,147
+/- 1,489,366

Liabilities & Shareholders' Equity

Total Current Liabilities606,988
Long-term Liabilities723,962
Total Stockholder Equity5,657,990
Total Current Liabilities
Accounts payable 235,403
Other Current Liabilities 13,056
Total Current Liabilities  (as reported)606,988
Total Current Liabilities  (calculated)248,459
+/- 358,529
Long-term Liabilities
Long term Debt 595,138
Capital Lease Obligations Min Short Term Debt7,574
Long-term Liabilities Other 128,824
Long-term Liabilities  (as reported)723,962
Long-term Liabilities  (calculated)731,536
+/- 7,574
Total Stockholder Equity
Total Stockholder Equity (as reported)5,657,990
Total Stockholder Equity (calculated)0
+/- 5,657,990
Other
Capital Stock191
Common Stock Shares Outstanding 190,761
Net Invested Capital 6,253,128
Net Working Capital 2,625,439
Property Plant and Equipment Gross 1,934,832



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
4,435,398
4,393,384
4,558,128
4,690,039
4,722,841
5,302,110
6,158,090
5,848,020
5,805,053
5,898,496
5,977,475
6,003,325
6,062,707
6,145,841
6,264,040
6,375,074
6,433,695
6,563,172
6,758,163
6,841,603
6,872,673
7,067,121
6,851,195
6,988,940
6,988,9406,851,1957,067,1216,872,6736,841,6036,758,1636,563,1726,433,6956,375,0746,264,0406,145,8416,062,7076,003,3255,977,4755,898,4965,805,0535,848,0206,158,0905,302,1104,722,8414,690,0394,558,1284,393,3844,435,398
   > Total Current Assets 
1,916,855
1,806,768
1,859,359
1,942,143
2,116,249
2,647,566
2,738,979
2,342,219
2,288,766
2,357,837
2,311,570
2,274,385
2,394,024
2,517,598
2,682,701
2,751,457
2,842,105
2,950,117
2,955,308
2,956,088
2,985,012
3,259,630
3,056,590
3,232,427
3,232,4273,056,5903,259,6302,985,0122,956,0882,955,3082,950,1172,842,1052,751,4572,682,7012,517,5982,394,0242,274,3852,311,5702,357,8372,288,7662,342,2192,738,9792,647,5662,116,2491,942,1431,859,3591,806,7681,916,855
       Cash And Cash Equivalents 
364,369
307,577
423,221
437,446
476,632
818,900
1,015,675
649,158
667,313
641,533
617,143
587,276
605,440
619,802
761,515
724,531
580,074
694,381
785,414
755,127
746,996
972,150
675,448
942,842
942,842675,448972,150746,996755,127785,414694,381580,074724,531761,515619,802605,440587,276617,143641,533667,313649,1581,015,675818,900476,632437,446423,221307,577364,369
       Short-term Investments 
530,485
423,526
297,572
316,361
381,764
561,472
489,998
416,228
420,178
481,864
462,333
426,599
450,798
489,945
512,253
567,006
572,017
476,577
340,431
318,683
299,584
252,201
254,996
194,864
194,864254,996252,201299,584318,683340,431476,577572,017567,006512,253489,945450,798426,599462,333481,864420,178416,228489,998561,472381,764316,361297,572423,526530,485
       Net Receivables 
393,429
377,150
402,970
377,404
396,384
381,215
411,712
448,351
396,097
424,419
374,937
373,399
430,147
466,507
419,622
461,316
597,913
610,222
572,498
633,704
637,163
691,232
777,547
660,535
660,535777,547691,232637,163633,704572,498610,222597,913461,316419,622466,507430,147373,399374,937424,419396,097448,351411,712381,215396,384377,404402,970377,150393,429
       Inventory 
534,696
578,736
609,049
680,275
705,652
743,852
700,847
698,548
713,929
710,975
749,406
776,669
786,356
802,315
839,460
894,083
918,921
975,546
1,032,159
1,107,183
1,137,982
1,183,621
1,179,339
1,232,653
1,232,6531,179,3391,183,6211,137,9821,107,1831,032,159975,546918,921894,083839,460802,315786,356776,669749,406710,975713,929698,548700,847743,852705,652680,275609,049578,736534,696
       Other Current Assets 
93,876
119,779
126,547
130,657
155,817
142,127
120,747
129,934
91,249
99,046
107,751
110,442
121,283
139,029
149,851
104,521
173,180
193,391
224,806
141,391
163,287
160,426
169,260
201,533
201,533169,260160,426163,287141,391224,806193,391173,180104,521149,851139,029121,283110,442107,75199,04691,249129,934120,747142,127155,817130,657126,547119,77993,876
   > Long-term Assets 
2,518,543
2,586,616
2,698,769
2,747,896
2,606,592
2,654,544
3,419,111
3,505,801
3,922,190
3,540,659
3,665,905
3,728,940
3,668,683
3,628,243
3,581,339
3,623,617
3,591,590
3,613,055
3,802,855
3,885,515
3,887,661
3,807,491
3,794,605
3,756,513
3,756,5133,794,6053,807,4913,887,6613,885,5153,802,8553,613,0553,591,5903,623,6173,581,3393,628,2433,668,6833,728,9403,665,9053,540,6593,922,1903,505,8013,419,1112,654,5442,606,5922,747,8962,698,7692,586,6162,518,543
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,051,821
1,073,366
1,068,142
1,067,278
1,067,156
1,066,133
1,060,425
1,052,898
1,045,408
1,043,041
1,043,0411,045,4081,052,8981,060,4251,066,1331,067,1561,067,2781,068,1421,073,3661,051,82100000000000000
       Goodwill 
197,039
197,039
197,039
197,039
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199
196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199196,199197,039197,039197,039197,039
       Long Term Investments 
320,000
374,965
431,804
411,978
290,796
323,058
265,122
285,473
321,127
350,237
466,618
507,793
462,827
412,503
372,302
333,835
340,635
385,777
548,002
611,135
620,551
557,083
561,985
521,238
521,238561,985557,083620,551611,135548,002385,777340,635333,835372,302412,503462,827507,793466,618350,237321,127285,473265,122323,058290,796411,978431,804374,965320,000
       Intangible Assets 
485,981
476,632
462,849
456,580
443,717
433,381
427,172
417,271
811,806
394,298
388,487
388,652
374,251
369,368
354,024
338,569
325,989
310,343
302,476
294,701
279,653
265,533
260,920
255,278
255,278260,920265,533279,653294,701302,476310,343325,989338,569354,024369,368374,251388,652388,487394,298811,806417,271427,172433,381443,717456,580462,849476,632485,981
       Long-term Assets Other 
96,300
99,456
112,646
122,009
125,918
135,852
119,009
142,237
141,198
141,663
144,705
151,760
149,186
151,797
151,788
176,236
150,057
144,168
165,069
171,538
184,790
190,772
199,314
251,391
251,391199,314190,772184,790171,538165,069144,168150,057176,236151,788151,797149,186151,760144,705141,663141,198142,237119,009135,852125,918122,009112,64699,45696,300
> Total Liabilities 
1,498,771
1,432,430
1,483,723
1,567,658
1,482,879
2,065,431
2,104,197
1,742,018
1,643,043
1,656,925
1,711,326
1,732,585
1,671,392
1,641,034
1,695,526
1,771,918
1,774,652
1,780,345
1,861,266
1,890,054
1,798,857
1,780,822
1,437,799
1,330,950
1,330,9501,437,7991,780,8221,798,8571,890,0541,861,2661,780,3451,774,6521,771,9181,695,5261,641,0341,671,3921,732,5851,711,3261,656,9251,643,0431,742,0182,104,1972,065,4311,482,8791,567,6581,483,7231,432,4301,498,771
   > Total Current Liabilities 
500,986
439,428
493,745
932,503
820,470
813,302
854,693
492,548
430,035
443,344
514,898
539,822
490,418
464,727
521,020
588,884
598,231
597,231
1,163,223
1,177,024
1,087,900
1,067,337
715,658
606,988
606,988715,6581,067,3371,087,9001,177,0241,163,223597,231598,231588,884521,020464,727490,418539,822514,898443,344430,035492,548854,693813,302820,470932,503493,745439,428500,986
       Short-term Debt 
0
0
0
361,882
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000361,882000
       Short Long Term Debt 
0
0
0
361,882
365,964
370,100
374,290
0
0
0
0
0
0
0
0
0
0
0
493,398
493,877
494,357
494,837
0
0
00494,837494,357493,877493,39800000000000374,290370,100365,964361,882000
       Accounts payable 
224,385
223,947
226,769
240,981
235,163
205,870
218,021
191,429
165,001
176,073
203,321
193,003
187,810
199,251
207,165
231,238
264,778
277,944
301,369
315,509
292,238
257,412
312,321
235,403
235,403312,321257,412292,238315,509301,369277,944264,778231,238207,165199,251187,810193,003203,321176,073165,001191,429218,021205,870235,163240,981226,769223,947224,385
       Other Current Liabilities 
6,904
6,423
8,731
10,448
7,675
7,435
7,774
17,798
39,452
43,246
53,510
54,495
64,000
29,954
28,303
28,526
15,956
19,572
10,584
33,853
13,676
7,684
14,301
13,056
13,05614,3017,68413,67633,85310,58419,57215,95628,52628,30329,95464,00054,49553,51043,24639,45217,7987,7747,4357,67510,4488,7316,4236,904
   > Long-term Liabilities 
997,785
993,002
989,978
635,155
662,409
1,252,129
1,249,504
1,249,470
1,213,008
1,213,581
1,196,428
1,192,763
1,180,974
1,176,307
1,174,506
1,183,034
1,176,421
1,183,114
698,043
713,030
710,957
713,485
722,141
723,962
723,962722,141713,485710,957713,030698,0431,183,1141,176,4211,183,0341,174,5061,176,3071,180,9741,192,7631,196,4281,213,5811,213,0081,249,4701,249,5041,252,129662,409635,155989,978993,002997,785
       Long term Debt 
834,766
839,165
843,616
486,238
486,713
1,073,202
1,074,164
1,075,145
1,076,127
1,077,110
1,078,093
1,079,077
1,080,061
1,081,047
1,082,033
1,083,019
1,084,006
1,084,994
592,586
593,095
593,605
594,116
594,627
595,138
595,138594,627594,116593,605593,095592,5861,084,9941,084,0061,083,0191,082,0331,081,0471,080,0611,079,0771,078,0931,077,1101,076,1271,075,1451,074,1641,073,202486,713486,238843,616839,165834,766
       Capital Lease Obligations Min Short Term Debt
9,210
10,165
10,225
-351,182
10,401
11,387
10,930
11,754
11,227
11,024
9,659
10,464
10,829
10,611
9,226
10,375
9,251
8,294
9,324
8,779
8,574
10,689
8,060
7,574
7,5748,06010,6898,5748,7799,3248,2949,25110,3759,22610,61110,82910,4649,65911,02411,22711,75410,93011,38710,401-351,18210,22510,1659,210
       Long-term Liabilities Other 
114,558
103,686
97,432
98,124
125,172
128,711
121,237
114,195
107,728
136,471
118,335
113,686
100,913
95,260
92,473
100,015
92,415
98,120
105,457
119,935
117,352
119,369
127,514
128,824
128,824127,514119,369117,352119,935105,45798,12092,415100,01592,47395,260100,913113,686118,335136,471107,728114,195121,237128,711125,17298,12497,432103,686114,558
> Total Stockholder Equity
2,936,627
2,960,954
3,074,405
3,122,381
3,239,962
3,236,679
4,053,893
4,106,002
4,162,010
4,241,571
4,266,149
4,270,740
4,391,315
4,504,807
4,568,514
4,603,156
4,659,043
4,782,827
4,896,897
4,951,549
5,073,816
5,286,299
5,413,396
5,657,990
5,657,9905,413,3965,286,2995,073,8164,951,5494,896,8974,782,8274,659,0434,603,1564,568,5144,504,8074,391,3154,270,7404,266,1494,241,5714,162,0104,106,0024,053,8933,236,6793,239,9623,122,3813,074,4052,960,9542,936,627
   Common Stock000000000000000000000000
   Retained Earnings Total Equity000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 000000000000000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue2,853,915
Cost of Revenue-580,235
Gross Profit2,273,6802,273,680
 
Operating Income (+$)
Gross Profit2,273,680
Operating Expense-2,379,719
Operating Income474,196-106,039
 
Operating Expense (+$)
Research Development747,184
Selling General Administrative1,009,000
Selling And Marketing Expenses0
Operating Expense2,379,7191,756,184
 
Net Interest Income (+$)
Interest Income74,883
Interest Expense-12,339
Other Finance Cost-391
Net Interest Income62,153
 
Pretax Income (+$)
Operating Income474,196
Net Interest Income62,153
Other Non-Operating Income Expenses0
Income Before Tax (EBT)541,763468,864
EBIT - interestExpense = -12,339
426,859
439,198
Interest Expense12,339
Earnings Before Interest and Taxes (EBIT)0554,102
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax541,763
Tax Provision-114,904
Net Income From Continuing Ops426,859426,859
Net Income426,859
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net5,332-62,153
 

Technical Analysis of BIOMARIN PHARM (BM8.SG)
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of BIOMARIN PHARM (BM8.SG). The general trend of BIOMARIN PHARM (BM8.SG) is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine BIOMARIN PHARM (BM8.SG)'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BIOMARIN PHARM (BM8.SG).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 68.16 < 68.16 < 68.22.

The bearish price targets are: 60.26 > 59.78 > 57.46.

Tweet this
BIOMARIN PHARM (BM8.SG) Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BIOMARIN PHARM (BM8.SG). The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BIOMARIN PHARM (BM8.SG) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BIOMARIN PHARM (BM8.SG). The current macd is 0.83415971.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the BIOMARIN PHARM (BM8.SG) price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for BIOMARIN PHARM (BM8.SG). This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the BIOMARIN PHARM (BM8.SG) price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
BIOMARIN PHARM (BM8.SG) Daily Moving Average Convergence/Divergence (MACD) ChartBIOMARIN PHARM (BM8.SG) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BIOMARIN PHARM (BM8.SG). The current adx is 26.44.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy BIOMARIN PHARM (BM8.SG) shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
BIOMARIN PHARM (BM8.SG) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BIOMARIN PHARM (BM8.SG). The current sar is 67.49.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
BIOMARIN PHARM (BM8.SG) Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BIOMARIN PHARM (BM8.SG). The current rsi is 52.88. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
BIOMARIN PHARM (BM8.SG) Daily Relative Strength Index (RSI) ChartBIOMARIN PHARM (BM8.SG) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BIOMARIN PHARM (BM8.SG). The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the BIOMARIN PHARM (BM8.SG) price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
BIOMARIN PHARM (BM8.SG) Daily Stochastic Oscillator ChartBIOMARIN PHARM (BM8.SG) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BIOMARIN PHARM (BM8.SG). The current cci is -13.84592724.

BIOMARIN PHARM (BM8.SG) Daily Commodity Channel Index (CCI) ChartBIOMARIN PHARM (BM8.SG) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BIOMARIN PHARM (BM8.SG). The current cmo is 1.02299259.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
BIOMARIN PHARM (BM8.SG) Daily Chande Momentum Oscillator (CMO) ChartBIOMARIN PHARM (BM8.SG) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BIOMARIN PHARM (BM8.SG). The current willr is -73.01587302.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that BIOMARIN PHARM (BM8.SG) is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
BIOMARIN PHARM (BM8.SG) Daily Williams %R ChartBIOMARIN PHARM (BM8.SG) Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BIOMARIN PHARM (BM8.SG).

BIOMARIN PHARM (BM8.SG) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BIOMARIN PHARM (BM8.SG). The current atr is 1.16136637.

BIOMARIN PHARM (BM8.SG) Daily Average True Range (ATR) ChartBIOMARIN PHARM (BM8.SG) Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BIOMARIN PHARM (BM8.SG). The current obv is 743.00.

BIOMARIN PHARM (BM8.SG) Daily On-Balance Volume (OBV) ChartBIOMARIN PHARM (BM8.SG) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BIOMARIN PHARM (BM8.SG). The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
BIOMARIN PHARM (BM8.SG) Daily Money Flow Index (MFI) ChartBIOMARIN PHARM (BM8.SG) Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BIOMARIN PHARM (BM8.SG).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-21ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-28ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

BIOMARIN PHARM (BM8.SG) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BIOMARIN PHARM (BM8.SG) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.878
Ma 20Greater thanMa 5065.222
Ma 50Greater thanMa 10063.096
Ma 100Greater thanMa 20062.761
OpenGreater thanClose64.300
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of BIOMARIN PHARM (BM8.SG) with someone you think should read this too:
  • Are you bullish or bearish on BIOMARIN PHARM (BM8.SG)? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about BIOMARIN PHARM (BM8.SG)? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BIOMARIN PHARM (BM8.SG)

I send you an email if I find something interesting about BIOMARIN PHARM (BM8.SG).


Comments

How you think about this?

Leave a comment

Stay informed about BIOMARIN PHARM (BM8.SG).

Receive notifications about BIOMARIN PHARM (BM8.SG) in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.